Researchers resolve decades-old mystery about the most commonly mutated gene in cancer

September 18, 2018 by Rob Levy, Broad Institute of MIT and Harvard
Researchers resolve decades-old mystery about the most commonly mutated gene in cancer
Lung cancer cells (red), one of the many forms of cancer affected by TP53 mutations. Credit: National Cancer Institute \ Fox Chase Cancer Center

The most commonly mutated gene in cancer has tantalized scientists for decades about the message of its mutations. Although mutations can occur at more than 1,100 sites within the TP53 gene, they arise with greatest frequency at a handful of points dubbed "hot spots." Does this imbalance suggest that hotspot mutations are especially conducive to cancer or that they're particularly disabling to TP53? What does the plethora of mutations at hot spots tell scientists about the role of TP53 within cells and about the ability of certain mutations to disrupt that role?

A study published today in Nature Genetics by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and other institutions reveals that hotspot mutations aren't so special, after all—that they are no more -promoting than many other mutations are, and are simply artifacts of the processes by which cells acquire mutations. The discovery, which involved making every possible mutation in TP53 and testing all of them in cells, led to the creation of an online tool that physicians and researchers can use to learn the effect of any TP53 mutation they encounter.

"As tumors are increasingly sequenced to identify mutations vulnerable to targeted therapies, it's important that we be able to know the function of those mutations and how they affect tumor cells," says William Hahn, senior author of the study, deputy chief scientific officer at Dana-Farber, an institute member in the Broad's Cancer Program, and a faculty member at Brigham and Women's Hospital. "Our work in TP53 suggests that this information can be compiled for virtually any gene."

TP53 is a tumor-suppressor gene that works by placing a damper on cell division and prevents cells from growing and multiplying out of control. When mutated—when the DNA code within the gene is misspelled—the gene may lose its normal function, allowing cell growth to run rampant. Mutations in TP53 are found in virtually every type of cancer, at rates of up to 50 percent in ovarian, esophageal, colorectal, head and neck, laryngeal, and lung cancers. People born with mutated forms of the gene are at exceptionally high risk of developing an array of different cancers.

While mutations can theoretically arise anywhere along the chain of DNA that comprises TP53—and while hundreds of such mutations have been found in tumor samples—mutations are more likely to occur in five or six hot spots than anywhere else. Researchers have speculated that cancer cells may favor hot spot mutations because such mutations are particularly disabling to TP53, weakening its grip on cell growth more than other mutations do. Some have theorized that because the hot spot mutations are of a type normally found in oncogenes—which spur cancer growth—TP53 may have a hitherto-undetected oncogenic role.

To resolve these questions, Hahn and his colleagues used technology unavailable only a few years ago to create a library of 8,258 variants of TP53, representing all the mutations that could arise in the gene. The variants were then placed in cells to see what effect they would have on .

"We found that hotspot mutations were no more oncogenic—no more likely to promote cancer—than many other mutations," Hahn remarks. "The tendency of mutations to arise in the hot spots is, rather, tied to processes by which mutations occur.

"A variety of factors can cause mutations—ultraviolet light, DNA-damaging chemicals, etc.," Hahn explains. "Certain carcinogens [cancer-causing substances] tend to target certain DNA sequences—specifically, those sequences that are more easily mutated. The array of mutations that we see in TP53 reflects the nature of the carcinogens to which cells are exposed."

Different tissues in the body tend to be exposed to different carcinogens—lung cells to carcinogens in tobacco smoke, for example, or colon cells to carcinogens in food. Researchers used the data they'd collected to predict how frequently TP53 mutations would arise in different varieties of cancer. When they matched their predictions against online data about the prevalence of TP53 mutations in various cancer types, their predictions were borne out.

"This indicates we're correct that mutations in TP53 are focused on certain because those spots are targeted by the specific carcinogens to which cells are exposed," Hahn says. "Understanding the role played by specific within cancer-related will become increasingly important as gene sequencing takes on a larger role in cancer treatment. Our work is a significant step toward that goal."

Explore further: Scientists develop a sensor for the most important human cancer gene

More information: Andrew O. Giacomelli et al. Mutational processes shape the landscape of TP53 mutations in human cancer, Nature Genetics (2018). DOI: 10.1038/s41588-018-0204-y

Related Stories

Scientists develop a sensor for the most important human cancer gene

November 14, 2017
If it burns in a house smoke detectors alert us hence protecting life. A molecular smoke alert has now been developed by Dresden researchers for the TP53 gene, the most important human cancer gene. The alert goes on if the ...

Germline TP53 mutations in patients with early-onset colorectal cancer

March 12, 2015
In a group of patients diagnosed with colorectal cancer at 40 or younger, 1.3 percent of the patients carried germline TP53 gene mutations, although none of the patients met the clinical criteria for an inherited cancer syndrome ...

Mutations unveiled that predispose lung cancers to refractory histologic transformation

June 7, 2017
Cancer pedigree analysis reveals the mutations in RB1 and TP53 genes play a key role in treatment-resistant, cancer cell-type transformation during EGFR inhibitor therapy for lung cancers.

New clues found to understanding relapse in breast cancer

September 4, 2018
A large genomic analysis has linked certain DNA mutations to a high risk of relapse in estrogen receptor positive breast cancer, while other mutations were associated with better outcomes, according to researchers from Washington ...

Research enforces importance of studying rare, recurrent somatic mutations in ER+ breast cancer

September 5, 2018
Recent research and genomic studies have revealed a number of genes that accumulate somatic, or non-inherited, mutations and alterations in estrogen receptor positive (ER+) breast cancer. However, while a few alterations ...

Genetic test identifies 'high risk' lymphatic cancer patients

February 20, 2018
Around 1,500 people in Denmark are diagnosed with lymphatic cancer each year. A small sub-group (70 to 80 people) develop a rare and aggressive type of lymphatic cancer, known as mantle cell lymphoma (MCL).

Recommended for you

Genetic changes associated with physical activity reported

December 10, 2018
Time spent sitting, sleeping and moving is determined in part by our genes, University of Oxford researchers have shown. In one of the most detailed projects of its kind, the scientists studied the activity of 91,105 UK Biobank ...

Team seeks to create genetic map of worm's nervous system

December 10, 2018
How do you build a brain? What "rules" govern where neurons end up, how they connect to each other, and which functions they perform?

Scientists cut main heart disease risk locus out of DNA by genome editing

December 6, 2018
Over the past decade we've learned that billions of people carry a mysterious specter in their DNA that strongly increases their risk for life threatening cardiovascular diseases, such as heart attacks, aneurysms or strokes, ...

What can a snowflake teach us about how cancer spreads in the body?

December 6, 2018
What can seashells, lightning and the coastline of Britain teach us about new drugs for cancer?

New genetic insight could help treat rare debilitating heart and lung condition

December 6, 2018
The largest study of genetic variation in patients with pulmonary arterial hypertension has associated two important genes with the disease.

Are scientists studying the wrong kind of mice?

December 5, 2018
Mice represent well over half of the non-human subjects of biomedical research, and the vast majority of those mice are inbred. Formed by generation after generation of mating between brothers and sisters, inbred mice are ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.